We believe patients deserve better medicines. Our mission is to help biotech, venture capitalists and pharma improve their pipeline investments using human genetics.
Approximately 95% of drug development programs fail—most often because the drug’s target is not causal. We and others have recognized that human genetics is the most efficient way to reliably identify causal drug targets.
Drug development programs supported by human genetics are 2-4-fold more likely to reach the market. Because of this, large pharma often refuse to fund drug development programs unless they are strongly supported by human genetic evidence.
We are academics who have worked for 16 years generating, analyzing and critiquing human genetic evidence. We launched 5 Prime Sciences to provide these services to biotech, venture capitalists and pharmaceutical companies.
To do so we are committed to standing on the forefront of advances in human genetics, bioinformatics, clinical medicine and AI to deliver better medicines to our patients.